{"title": "Regeneron wins FDA approval for rare immune disease med Veopoz", "author": "Zoey Becker", "url": "https://www.fiercepharma.com/pharma/regeneron-wins-approval-rare-immune-disease-med-veopoz-expects-high-dose-eylea-nod-next-few", "hostname": "fiercepharma.com", "description": "Along with resolving site inspection issues that cost Regeneron a high-dose Eylea launch in June, the company has scored an FDA nod for Veopoz as the first treatment for the ultra-rare inherited im | Alongside a Friday approval for its ultra-rare disease medicine Veopoz, Regeneron also got a delayed nod for high-dose Eylea after resolving manufacturing issues at third-party filler Catalent.", "sitename": "FiercePharma", "date": "2023-08-19", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}